Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov;63(11):1628–1635. doi: 10.2967/jnumed.121.263124

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

PMC Copyright notice

FIGURE 1. — BCR (PSA, 14.1 ng/mL) in patient with CRPC who was previously treated with radical prostatectomy, salvage radiation therapy to prostate bed, and ADT. ¹⁸F-fluciclovine (Axumin) PET/CT (first panel) showed single oligometastasis in proximal right femur (arrow), which was treated with SABR, with initial transient decline in PSA level but rapid subsequent rise within 3 mo to 15.5 ng/mL. ⁶⁸Ga-PSMA PET/CT (second panel) showed heterogeneous activity in proximal right femur and additional metastatic lesions in right ribs (arrows). Serum PSA level rose rapidly again within 2 mo to 84.4 ng/mL, at which time repeat ⁶⁸Ga-PSMA-11 PET/CT (third panel) showed numerous metastases. Companion ¹⁸F-FDG PET/CT showed that some metastases also exhibited high glycolytic phenotype (fourth panel). Patient was enrolled in clinical trial. All images are maximum-intensity projections. RP = radical prostatectomy; SBRT = stereotactic body radiation therapy. (Courtesy of Jeremie Calais, UCLA.)